# Trastuzumab in HER2-positive Biliary Tract Cancer

> **NCT03613168** · PHASE2 · COMPLETED · sponsor: **Changhoon Yoo** · enrollment: 4 (actual)

## Conditions studied

- Cholangiocarcinoma
- Biliary Tract Cancer
- HER-2 Protein Overexpression
- HER-2 Gene Amplification

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT03613168
- **Lead sponsor:** Changhoon Yoo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2020-11-01
- **Final completion:** 2021-01-04
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613168, "Trastuzumab in HER2-positive Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03613168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*